Associated Papers
CYP genetic polymorphism, and CYP3A inducers and inhibitors regulate apatinib metabolism: Consequences for drug exposure and toxicity risks.
Wang Z et al.
Toxicology and Applied Pharmacology, 2026
Differential metabolism of citalopram by 21 CYP3A4 variants: An in vitro experiment.
Wang P et al.
Journal of Psychopharmacology (oxford, England), 2025
Decoding Allosteric Effects of Missense Variations in Drug Metabolism: Afrocentric CYP3A4 Alleles Explored.
Mwaniki RM et al.
Journal of Molecular Biology, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
In-silico screening and analysis of missense SNPs in human CYP3A4/5 affecting drug-enzyme interactions of FDA-approved COVID-19 antiviral drugs.
Abdelazim AA et al.
Scientific Reports, 2025
Effects of CYP3A4 Variants on Methadone Metabolism In Vitro.
Wang CC et al.
Biomedical Chromatography : Bmc, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.
Beunk L et al.
European Journal of Human Genetics : Ejhg, 2024
The effect of gene polymorphism on ticagrelor metabolism: an in vitro study of 22 CYP3A4 variants in Chinese Han population.
Hu X et al.
Peerj, 2024
Determine the enzymatic kinetic characteristics of CYP3A4 variants utilizing artemether-lumefantrine.
Zhang X et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?
Maslub MG et al.
European Journal of Medical Research, 2023
High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database.
Adachi K et al.
Drug Metabolism and Pharmacokinetics, 2023
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Comparison of genetic susceptibility to lung adenocarcinoma and squamous cell carcinoma in Japanese patients using a novel panel for cancer-related drug-metabolizing enzyme genes.
Ohnami S et al.
Scientific Reports, 2022
Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors.
Maekawa K et al.
Drug Metabolism and Pharmacokinetics, 2022
Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Liu Q et al.
Fundamental & Clinical Pharmacology, 2022
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.
Zhai Q et al.
Frontiers in Pharmacology, 2022
Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions.
Kong Q et al.
Frontiers in Pharmacology, 2022
Time-dependent inhibition of CYP3A4-mediated midazolam metabolism by macrolide antibiotics in CYP3A4 genetic variants: Comparison with testosterone metabolism.
Akiyoshi T et al.
International Journal of Clinical Pharmacology and Therapeutics, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6β-Hydroxylation.
Kumondai M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism.
Chen B et al.
Chemical Research in Toxicology, 2020
Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro.
Yang CC et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2019
Polymorphism in Cytochrome P450 3A4 Is Ethnicity Related.
Guttman Y et al.
Frontiers in Genetics, 2019
Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro.
Zhou XY et al.
Frontiers in Pharmacology, 2019
Population genetic difference of pharmacogenomic VIP gene variants in the Lisu population from Yunnan Province.
Zhang C et al.
Medicine, 2018
Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2018
Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy.
Apellániz-Ruiz M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro.
Fang P et al.
Drug Design, Development and Therapy, 2017
Sodium tanshinone IIA sulfonate and its interactions with human CYP450s.
Chen D et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2016
ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.
Fukunaga K et al.
Bmc Genetics, 2016
Contrasting exome constancy and regulatory region variation in the gene encoding CYP3A4: an examination of the extent and potential implications.
Creemer OJ et al.
Pharmacogenetics and Genomics, 2016
Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment.
Yi S et al.
Pharmacogenetics and Genomics, 2014
Functional gene variants of CYP3A4.
Werk AN et al.
Clinical Pharmacology and Therapeutics, 2014
Genetic polymorphisms associated with antiepileptic metabolism.
Lopez-Garcia MA et al.
Frontiers in Bioscience (elite Edition), 2014
[Pharmacogenetics and antiepileptic drug metabolism: implication of genetic variants in cytochromes P450].
Saldaña-Cruz AM et al.
Revista De Neurologia, 2013
A population-specific uncommon variant in GRIN3A associated with schizophrenia.
Takata A et al.
Biological Psychiatry, 2013
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.
Fountzilas G et al.
Plos One, 2013
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
Wang D et al.
Journal of Personalized Medicine, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Sai K et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
Akiyoshi T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2011
Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Sato Y et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2011
Evaluation of the effects of cytochrome P450 nonsynonymous single-nucleotide polymorphisms on tanshinol borneol ester metabolism and inhibition potential.
Liu D et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2010
CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.
Maekawa K et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2010
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman SS et al.
Pharmacogenomics, 2009
A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450.
Wang LL et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine.
Maekawa K et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2009
Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.
Miyazaki M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2008